Skip to content
Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=dfc81ac7-0f0b-40b0-8404-972274eb8d52
Date
8/10/2016
Company Name
Iconic Therapeutics
Mailing Address
395 Oyster Point Boulevard South San Francisco, CA 94080 USA
Company Description
Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells.
Website
http://www.iconictherapeutics.com
Transaction Type
Venture Equity
Transaction Amount
$10,000,000
Transaction Round
Series C
Proceeds Purposes
Proceeds from the financing will be used to advance development of Iconic’s lead molecule ICON-1 in retinal diseases as well begin clinical trials in ocular melanoma, Iconic’s first oncology indication.
M&A Terms
Venture Investor
Xeraya Capital
Venture Investor
MPM Capital
Venture Investor
HBM BioCapital
Venture Investor
H.I.G. Capital
Venture Investor
Lundbeckfond Ventures
Venture Investor
Cormorant Asset Management
Venture Investor
Osage Partners
Post navigation